Page last updated: 2024-11-13
psammaplysin f
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
psammaplysin F: isolated from sponge, Aplysinella sp.; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 46888580 |
CHEMBL ID | 1095507 |
MeSH ID | M0280259 |
Synonyms (3)
Synonym |
---|
CHEMBL1095507 |
psammaplysin f |
bdbm50493051 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (20)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID478227 | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 after 72 hrs by fluorescence assay | 2010 | Journal of natural products, May-28, Volume: 73, Issue:5 | Antimalarial bromotyrosine derivatives from the Australian marine sponge Hyattella sp. |
AID766159 | Antibacterial activity against methicillin-resistant Staphylococcus aureus MW2 assessed as growth inhibition at 50 uM after 5 hrs by BacTiter-Glo microbial assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766174 | Antibacterial activity against Enterococcus faecalis NCTC 775 after 20 to 24 hrs by two-fold broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID478226 | Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum 3D7 after 72 hrs by fluorescence assay | 2010 | Journal of natural products, May-28, Volume: 73, Issue:5 | Antimalarial bromotyrosine derivatives from the Australian marine sponge Hyattella sp. |
AID766172 | Antibacterial activity against Bacillus cereus NCTC 7464 after 20 to 24 hrs by two-fold broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766175 | Antibacterial activity against Staphylococcus aureus 1H after 20 to 24 hrs by two-fold broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766160 | Antibacterial activity against Staphylococcus aureus 1H assessed as daughter cells lacking DNA at half MIC after 5 hrs by three dimensional structured illumination microscopy | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766170 | Disruption of plasma membrane integrity in Staphylococcus aureus 1H assessed as extracellular ATP release at 20 uM after 15 to 120 mins by BacTiter-Glo microbial assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766176 | Antibacterial activity against Staphylococcus aureus NCTC 6571 after 20 to 24 hrs by two-fold broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766183 | Antibacterial activity against penicillin-resistant Staphylococcus aureus 1H assessed as growth inhibition at 50 uM after 5 hrs by BacTiter-Glo microbial assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766173 | Antibacterial activity against methicillin-resistant Staphylococcus aureus MW2 after 20 to 24 hrs by two-fold broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766166 | Antibacterial activity against Staphylococcus aureus 1H assessed as small daughter cells without swelling at half MIC after 5 hrs by phase contrast microscopy | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766182 | Antibacterial activity against Enterococcus faecalis NCTC 775 assessed as growth inhibition at 50 uM after 5 hrs by BacTiter-Glo microbial assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766161 | Antibacterial activity against Staphylococcus aureus 1H assessed as improper segregation of chromosome at half MIC after 5 hrs by three dimensional structured illumination microscopy | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766171 | Antibacterial activity against methicillin-resistant Staphylococcus aureus USA-300 after 20 to 24 hrs by two-fold broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766181 | Antibacterial activity against Bacillus cereus NCTC 7464 assessed as growth inhibition at 50 uM after 5 hrs by BacTiter-Glo microbial assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766184 | Antibacterial activity against Staphylococcus aureus NCTC 6571 assessed as growth inhibition at 50 uM after 5 hrs by BacTiter-Glo microbial assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID478229 | Cytotoxicity against human HEK293 cells after 72 hrs by Alamar blue assay | 2010 | Journal of natural products, May-28, Volume: 73, Issue:5 | Antimalarial bromotyrosine derivatives from the Australian marine sponge Hyattella sp. |
AID766168 | Antibacterial activity against Staphylococcus aureus 1H assessed as long branch like strings of cellular debris at half MIC after 5 hrs by phase contrast microscopy | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
AID766158 | Antibacterial activity against methicillin-resistant Staphylococcus aureus USA-300 assessed as growth inhibition at 50 uM after 5 hrs by BacTiter-Glo microbial assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 | Psammaplysin F: a unique inhibitor of bacterial chromosomal partitioning. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.13
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.13) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |